BPG is committed to discovery and dissemination of knowledge
Featured Articles
6/26/2020 10:42:52 AM | Browse: 432 | Download: 724
Publication Name World Journal of Stem Cells
Manuscript ID 56477
Country/Territory United States
Received
2020-05-01 20:41
Peer-Review Started
2020-05-01 20:42
To Make the First Decision
Return for Revision
2020-05-15 06:55
Revised
2020-05-17 07:08
Second Decision
2020-05-21 12:03
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-05-22 05:04
Articles in Press
2020-05-22 05:04
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2020-06-18 09:38
Publish the Manuscript Online
2020-06-25 10:09
ISSN 1948-0210 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Respiratory System
Manuscript Type Minireviews
Article Title Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials
Manuscript Source Invited Manuscript
All Author List Hong-Long Ji, Cong Liu and Run-zhen Zhao
Funding Agency and Grant Number
Funding Agency Grant Number
NIH HL87017
Corresponding Author Hong-Long Ji, MD, PhD, Director, Professor, Department of Cellular and Molecular Biology, Texas Lung Injury Institute, University of Texas Health Science Center at Tyler, 11937 U.S. Highway 271, Tyler, TX 75708, United States. james.ji@uthct.edu
Key Words Pulmonary diseases; COVID-19; Cell therapy; Exosomes; Clinical trial;
Core Tip Preclinical studies demonstrate significant improvement of lung disorders by stem cells and extracellular vesicles. Completed clinical trials show cell-based therapies are safe and tolerant for acute and chronic respiratory diseases. Current challenges for cell therapy of pulmonary illnesses are long-term safety, efficacy, and personal medicines.
Publish Date 2020-06-25 10:09
Citation Ji HL, Liu C, Zhao RZ. Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials. World J Stem Cells 2020; 12(6): 471-480
URL https://www.wjgnet.com/1948-0210/full/v12/i6/471.htm
DOI https://dx.doi.org/10.4252/wjsc.v12.i6.471
Full Article (PDF) WJSC-12-471.pdf
Full Article (Word) WJSC-12-471.docx
Manuscript File 56477-Review.doc
Answering Reviewers 56477-Answering reviewers.pdf
Audio Core Tip 56477-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 56477-Conflict-of-interest statement.pdf
Copyright License Agreement 56477-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 56477-Grant application form(s).PDF
Supplementary Material 56477-Supplementary material.xls
Peer-review Report 56477-Peer-review(s).pdf
Scientific Misconduct Check 56477-Scientific misconduct check.pdf
Scientific Editor Work List 56477-Scientific editor work list.pdf